- Home
- TRC vs XOMAO Comparison
TRC vs XOMAO Comparison
Compare TRC & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- XOMAO
- Stock Information
- Founded
- TRC 1843
- XOMAO N/A
- Country
- TRC United States
- XOMAO United States
- Employees
- TRC N/A
- XOMAO 13
- Industry
- TRC Real Estate
- XOMAO Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- XOMAO Health Care
- Exchange
- TRC Nasdaq
- XOMAO Nasdaq
- Market Cap
- TRC N/A
- XOMAO N/A
- IPO Year
- TRC N/A
- XOMAO N/A
- Fundamental
- Price
- TRC $15.87
- XOMAO $25.39
- Analyst Decision
- TRC
- XOMAO
- Analyst Count
- TRC 0
- XOMAO 0
- Target Price
- TRC N/A
- XOMAO N/A
- AVG Volume (30 Days)
- TRC 139.5K
- XOMAO N/A
- Earning Date
- TRC 03-06-2025
- XOMAO N/A
- Dividend Yield
- TRC N/A
- XOMAO N/A
- EPS Growth
- TRC N/A
- XOMAO N/A
- EPS
- TRC 0.10
- XOMAO N/A
- Revenue
- TRC $41,886,000.00
- XOMAO N/A
- Revenue This Year
- TRC $10.98
- XOMAO N/A
- Revenue Next Year
- TRC N/A
- XOMAO N/A
- P/E Ratio
- TRC $160.80
- XOMAO N/A
- Revenue Growth
- TRC N/A
- XOMAO N/A
- 52 Week Low
- TRC $14.71
- XOMAO N/A
- 52 Week High
- TRC $19.82
- XOMAO N/A
- Technical
- Relative Strength Index (RSI)
- TRC 48.93
- XOMAO 52.06
- Support Level
- TRC $15.62
- XOMAO $25.42
- Resistance Level
- TRC $16.71
- XOMAO $25.46
- Average True Range (ATR)
- TRC 0.38
- XOMAO 0.05
- MACD
- TRC 0.01
- XOMAO 0.00
- Stochastic Oscillator
- TRC 22.94
- XOMAO 79.10
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.